STAT1 and hepatocellular carcinoma: Moreover, recent reports demonstrated that IL-1β can activate the STAT1 pathway by negatively modulating ERK2 activation in the target cells [38] and synergistically elevates PD-L1 expression through the coordination with IFNγ in hepatocellular carcinoma [39].